The selection of drug substance Regulatory Starting Materials (RSMs) and justification of their designation in the pharmaceutical supply chain has become an industry-wide focus as a measure of mitigating regulatory risks, as well as preventing unexpected rises in cost when transitioning from clinical to commercial supply chains. So RSM’s are the key intermediates in the synthesis of API, Dasha Pharmaceuticals offers methodology of RSM synthesis and fulfil the Global needs as supplier for customer API’s under GMP synthesis and extend the document support for smooth filing.